Urothelial Carcinoma - Pipeline Insight, 2024

This Urothelial Carcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Urothelial Carcinoma Understanding

Urothelial Carcinoma: Overview

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. In fact, if you have bladder cancer it's almost certain to be an urothelial carcinoma. These cancers start in the urothelial cells that line the inside of the bladder. Urothelial cells also line other parts of the urinary tract, such as the part of the kidney that connects to the ureter (called the renal pelvis), the ureters, and the urethra. People with bladder cancer sometimes have tumors in these places, too, so all of the urinary tract needs to be checked for tumors.

Urothelial Carcinoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Urothelial Carcinoma pipeline landscape is provided which includes the disease overview and Urothelial Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Urothelial Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Urothelial Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Urothelial Carcinoma.

This segment of the Urothelial Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Urothelial Carcinoma Drugs
Pemazyre (pemigatinib): IncytePemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

Cetrelimab: Janssen Research and DevelopmentCetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio.

Urothelial Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the Urothelial Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Urothelial Carcinoma

There are approx. 40+ key companies which are developing the therapies for Urothelial Carcinoma. The companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include Janssen Research and Development.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Urothelial Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Urothelial Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Urothelial Carcinoma drugs.

Urothelial Carcinoma Report Insights

• Urothelial Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Urothelial Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Urothelial Carcinoma drugs?
• How many Urothelial Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Urothelial Carcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Urothelial Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Urothelial Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MedPacto
• AstraZeneca
• Helsinn/QED Therapeutics
• Inovio Pharmaceuticals
• Abbisko Therapeutics
• Bayer
• 4D pharma plc
• RemeGen
• Infinity Pharmaceuticals
• Kyowa Kirin, Inc.
• Ikena Oncology
• Vyriad
• Seagen
• RemeGen
• Pfizer
• Incyte Corporation
• Prestige BioPharma
• TARIS Biomedical
• Janssen Research and Development

Key Products

• Vactosertib
• Infigratinib
• INO-5401
• AZD4547
• Rogaratinib
• MRx0518
• RC48-ADC
• IPI-549
• KHK2455
• IK-175
• MV NIS
• Enfortumab vedotin
• PF-06801591
• Pemigatinib
• Erdafitinib
• Gemcitabine controlled release
• Trastuzumab biosimilar
• Cetrelimab

This product will be delivered within 1-3 business days.